THE MEDICINES COMPANY INVESTIGATION

Gilman Law LLP is Investigating The Medicines Company on Behalf of Purchasers of The Medicines Company Stock

About the The Medicines Company
The Investment Fraud Attorneys of Gilman Law LLP announce they are investigating potential federal securities law claims on behalf of investors in The Medicines Company (NASDAQ:MDCO) common stock.

The Medicines Company Details of Investigation
On April 9, 2015, The Medicines Company announced that it expects net revenue in the range of $125 million to $140 million for the first quarter of 2015, which reflects a 29% to 26% decrease from the first quarter of 2014 due to lowering sales of Angiomax. The Company expects net revenue from sales of Angiomax to be in the range of $97 million to $105 million compared to $155.7 million in the first quarter of 2014. The Chairman and CEO of The Medicines Company, Clive Meanwell, stated that the declining sale of Angiomax “reflects our customers’ current uncertainty regarding the product’s patent exclusivity in the United States past June 2015” and that “[w]e appreciate our customers’ concerns about managing their pharmaceutical inventories.”

The Medicines Company

The Medicines Company Investigation

Legal Help for The Medicines Company Investors
If you purchased or otherwise acquired shares of The Medicines Company, you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.

About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.

For a free evaluation of your case or to obtain additional information, please CALL TOLL FREE (888) 252-0048.